Linvoseltamab Biosimilar - Research Grade

Human

CD3E + BCMA

5mg/ml

Human IgG4 (S228P)-kappa

https://www.imgt.org/mAb-DB/

ICH3002

P07766;Q02223

Blue ice

T-cell-redirecting bispecific antibodies that link CD3 to a tumour antigen are a major focus of immuno-oncology, and BCMA is a validated plasma-cell and multiple-myeloma target. This research-grade bispecific antibody is an unconjugated, non-therapeutic analog of linvoseltamab, engineered to co-engage CD3E and BCMA for preclinical study of T-cell-mediated cytotoxicity. It is validated for functional assays and intended strictly for research use only (RUO). Manufactured to in vivo grade standards as an ultra-pure, low-endotoxin formulation and offered in scalable milligram (mg) to gram (g) quantities, it serves heavy-usage and high-throughput laboratories conducting cytotoxicity assays, in vitro screening and in vivo tumour models.

This monoclonal antibody was purified using IEC

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.